The international consensus classification (ICC) now has TP53-mutated AML as a separate entity under “myeloid neoplasms with mutation TP53” to delineate the poor outcomes and highlight the need for better therapies irrespective of blast percent [50]. The gene discussed is TP53; the disease is myeloid neoplasm.